审视他汀类药物治疗与癌症患者生存研究中偏倚的探讨
该研究利用SEER-Medicare数据库17 372例新诊断结直肠癌、乳腺癌、前列腺癌或膀胱癌患者,采用模拟随机试验方法(将个体复制并随机分配至诊断后6个月内启动他汀治疗或不启动策略,用逆概率加权调整选择偏倚),发现他汀启动与未启动相比,癌症特异性死亡HR 1.00(95%CI 0.88-1.15),总死亡HR 1.07(95%CI 0.93-1.21),而先前研究方法得出他汀使用与死亡负相关(合并HR 0.69)。
要点
- 在避免选择偏倚和永恒时间偏倚后,诊断后6个月内启动他汀治疗未改善3年癌症特异性或总生存。
- 他汀启动 vs 未启动的癌症特异性死亡HR 1.00(95%CI 0.88-1.15),总死亡HR 1.07(95%CI 0.93-1.21)。
- 先前观察性研究方法得出他汀使用与死亡负相关(合并HR 0.69),可能源于偏倚。
核心结论
- 采用不易受现用药者选择偏倚和永恒时间偏倚影响的方法后,癌症诊断后6个月内启动他汀治疗似乎未改善3年癌症特异性或总生存。
研究设计与样本
- 利用SEER-Medicare数据库(2007-2009年)17 372例新诊断结直肠癌、乳腺癌、前列腺癌或膀胱癌患者,随访至2011年。
- 将每个个体复制并随机分配至诊断后6个月内启动他汀治疗或不启动策略,当偏离指派策略时删失,并用逆概率加权调整潜在选择偏倚。
- 计算全因死亡和癌症特异性死亡的风险比(HR)、累积发病率和风险差,并与先前观察性研究方法所得估计值比较。
主要发现
- 17 372例患者中,8440例(49%)为男性,8932例(51%)为女性(平均[SD]年龄76.4[7.4]岁;范围66-115岁)。
- 他汀启动 vs 未启动的癌症特异性死亡调整HR为1.00(95%CI 0.88-1.15),总死亡调整HR为1.07(95%CI 0.93-1.21)。
- 两组累积发病率曲线几乎重叠(风险差从未超过0.8%)。
- 先前研究所用方法得出他汀使用与死亡负相关(合并HR 0.69)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with cancer who use statins appear to have a substantially better survival than nonusers in observational studies. However, this inverse association between statin use and mortality may be due to selection bias and immortal-time bias. OBJECTIVE: To emulate a randomized trial of statin therapy initiation that is free of selection bias and immortal-time bias. DESIGN, SETTING, AND PARTICIPANTS: We used observational data on 17 372 patients with cancer from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2007-2009) with complete follow-up until 2011. The SEER-Medicare database links 17 US cancer registries and claims files from Medicare and Medicaid in 12 US states. We included individuals with a new diagnosis of colorectal, breast, prostate, or bladder cancer who had not been prescribed statins for at least 6 months before the cancer diagnosis. Individuals were duplicated, and each replicate was assigned to either the strategy "statin therapy initiation within 6 months after diagnosis" or "no statin therapy initiation." Replicates were censored when they stopped following their assigned strategy, and the potential selection bias was adjusted for via inverse-probability weighting. Hazard ratios (HRs), cumulative incidences, and risk differences were calculated for all-cause mortality and cancer-specific mortality. We then compared our estimates with those obtained using the same analytic approaches used in previous observational studies. EXPOSURES: Statin therapy initiation within 6 months after cancer diagnosis. MAIN OUTCOMES AND MEASURES: Cancer-specific and all-cause mortality using SEER-Medicare data and data from previous studies. RESULTS: Of the 17 372 patients whose data were analyzed, 8440 (49%) were men, and 8932 (51%) were women (mean [SD] age, 76.4 [7.4] years; range, 66-115 years). The adjusted HR (95% CI) comparing statin therapy initiation vs no initiation was 1.00 (0.88-1.15) for cancer-specific mortality and 1.07 (0.93-1.21) for overall mortality. Cumulative incidence curves for both groups were almost overlapping (the risk difference never exceeded 0.8%). In contrast, the methods used by prior studies resulted in an inverse association between statin use and mortality (pooled hazard ratio 0.69). CONCLUSION AND RELEVANCE: After using methods that are not susceptible to selection bias from prevalent users and to immortal time bias, we found that initiation of therapy with statins within 6 months after cancer diagnosis did not appear to improve 3-year cancer-specific or overall survival.
引用
- Emilsson L, García-Albéniz X, Logan RW, et al. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. JAMA Oncol. 2018. PMID: 28822996. doi:10.1001/jamaoncol.2017.2752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。